REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 21.9% in May

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 6,300,000 shares, a growth of 21.9% from the April 30th total of 5,170,000 shares. Currently, 14.6% of the shares of the stock are short sold. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 5.7 days.

REGENXBIO Price Performance

Shares of NASDAQ RGNX traded down $0.05 during midday trading on Wednesday, reaching $10.08. 690,256 shares of the company traded hands, compared to its average volume of 904,943. The company has a market cap of $505.61 million, a price-to-earnings ratio of -2.00 and a beta of 1.11. REGENXBIO has a 52 week low of $5.04 and a 52 week high of $15.36. The stock has a 50-day moving average price of $7.97 and a 200 day moving average price of $7.94.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The business had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, analysts expect that REGENXBIO will post -4.84 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RGNX shares. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. The Goldman Sachs Group decreased their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. Finally, HC Wainwright decreased their price target on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $31.63.

Insider Activity

In related news, Director Kenneth T. Mills sold 20,602 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the sale, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.79% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in REGENXBIO during the first quarter valued at approximately $1,123,000. Jane Street Group LLC lifted its stake in REGENXBIO by 151.1% in the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company's stock valued at $2,961,000 after acquiring an additional 249,156 shares in the last quarter. Exome Asset Management LLC bought a new position in REGENXBIO in the first quarter valued at approximately $2,898,000. AQR Capital Management LLC raised its stake in shares of REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock worth $4,437,000 after purchasing an additional 594,161 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of REGENXBIO by 86.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 350,352 shares of the biotechnology company's stock valued at $2,505,000 after buying an additional 162,423 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.